Psoriasis Vulgaris
Conditions
Brief summary
This study aims to assess the effect of adding N-acetyl cysteine (NAC) alone or in combination with Vitamin E to conventional therapy in improving the clinical outcome, oxidative stress, and inflammation in patients with mild psoriasis vulgaris
Detailed description
The study will include 60 Mild psoriatic patients in the active phase (score \<, =3) using PASI score. The PASI is a widely used instrument that assesses and grades the severity of psoriatic lesions and the patient's response to treatment. They will assigned randomly into 3 groups. Each group will contain 20 patients. the first group will receive Standard treatment for mild psoriatic patients (topical steroid and salicylic acid), the second group will receive Standard treatment for mild psoriasis, plus N acetyl cysteine (600 mg a day) oral, 30 minutes before breakfast, for 8 weeks. the third group will receive Standard treatment for mild psoriasis, plus N acetyl cysteine (600 mg a day) oral effervescent sachet,30 minutes before breakfast Plus, vitamin E (1000 mg) daily, oral soft gelatin capsule for 8 weeks. PASI=Psoriasis Area and Severity Index
Interventions
DRUGAcetyl cysteine
N-acetyl cysteine (NAC) is synthetic cysteine amino acid, which in turn elevate the glutathione level in the body, which have important direct antioxidant activity.
DRUGVitamin E
vitamin E possessing an anti-inflammatory action
Sponsors
Badr University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
1. Adult Patients from 18 to 65 years. 2. Gender: both males and females. 3. Mild psoriatic patients in the active phase (score \< =3) 4. Patients diagnosed with mild psoriasis in the active phase (score less than or equal 3) using PASI score.
Exclusion criteria
1. Inactive psoriasis vulgaris patients. 2. Alcohol consumption 3. Any other autoimmune diseases. 4. Pregnant or lactating women. 5. Patients with serious illness and any systemic failure (cardiovascular, renal, or respiratory) 6. Patients with major psychiatric or mental illness. 7. Intake of any antioxidants in the previous 3 months 8. Patients of chronic diseases, like hypertension, heart problems 9. Patients with history of bleeding, ulcers, or uncontrollable heartburn. 10. Patients taking anticancer medications that can aggravate psoriasis vulgaris such as mercaptopurine, vinblastine, actinomycin, and Radiation
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| level of interleukin-36(IL-36 gamma) (Pg/ml) | 4 months | measuring level of interleukin-36(IL-36 gamma) at baseline before the intervention and during taking the intervention and 1 month after stopping taking the intervention |
| level of Malondialdehyde (MDA) (µmol/L) | 4 months | measuring level of malondialdehyde (MDA) at baseline before the intervention and during taking the intervention and 1 month after stopping taking the intervention |
Countries
Egypt
Contacts
Primary ContactNira Elkalla
Backup ContactAmal Elkhouly
Outcome results
None listed